Gantenerumab fails; time for Roche to cut its Alzheimer's losses?
This article was originally published in Scrip
Roche is dropping a Phase III trial of the anti-amyloid gantenerumab in prodromal Alzheimer's disease patients. The decision calls into question not only the future of this drug, but also that of other disease modifying anti-amyloids, including Roche's crenezumab.
You may also be interested in...
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Two orphan drugs, Chiesi’s Proscybi and Insmed’s Arikayce, were rejected for funding on the Scottish National Health Service.
The Cuban government has approved the country’s home grown COVID-19 vaccine for emergency use in children, while Mexico is poised to authorize another Cuban vaccine.